- Home
- KPTI vs HSPO Comparison
KPTI vs HSPO Comparison
Compare KPTI & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- HSPO
- Stock Information
- Founded
- KPTI 2008
- HSPO 2014
- Country
- KPTI United States
- HSPO United States
- Employees
- KPTI N/A
- HSPO N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- HSPO Blank Checks
- Sector
- KPTI Health Care
- HSPO Finance
- Exchange
- KPTI Nasdaq
- HSPO Nasdaq
- Market Cap
- KPTI 66.7M
- HSPO 92.0M
- IPO Year
- KPTI 2013
- HSPO 2022
- Fundamental
- Price
- KPTI $7.44
- HSPO $11.73
- Analyst Decision
- KPTI Strong Buy
- HSPO
- Analyst Count
- KPTI 5
- HSPO 0
- Target Price
- KPTI $61.00
- HSPO N/A
- AVG Volume (30 Days)
- KPTI 146.0K
- HSPO 1.1K
- Earning Date
- KPTI 05-07-2025
- HSPO 01-01-0001
- Dividend Yield
- KPTI N/A
- HSPO N/A
- EPS Growth
- KPTI N/A
- HSPO 2.63
- EPS
- KPTI N/A
- HSPO 0.28
- Revenue
- KPTI $145,237,000.00
- HSPO N/A
- Revenue This Year
- KPTI $4.37
- HSPO N/A
- Revenue Next Year
- KPTI $19.07
- HSPO N/A
- P/E Ratio
- KPTI N/A
- HSPO $41.62
- Revenue Growth
- KPTI N/A
- HSPO N/A
- 52 Week Low
- KPTI $5.90
- HSPO $10.84
- 52 Week High
- KPTI $24.75
- HSPO $12.41
- Technical
- Relative Strength Index (RSI)
- KPTI 42.40
- HSPO 55.14
- Support Level
- KPTI $5.90
- HSPO $11.61
- Resistance Level
- KPTI $10.38
- HSPO $11.74
- Average True Range (ATR)
- KPTI 1.07
- HSPO 0.01
- MACD
- KPTI -0.06
- HSPO -0.00
- Stochastic Oscillator
- KPTI 34.37
- HSPO 68.24
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.